Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) EBITDA: 2015-2024

Historic EBITDA for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to -$71.7 million.

  • Outlook Therapeutics' EBITDA rose 21.10% to -$10.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$36.8 million, marking a year-over-year decrease of 1.49%. This contributed to the annual value of -$71.7 million for FY2024, which is 34.97% down from last year.
  • Outlook Therapeutics' EBITDA amounted to -$71.7 million in FY2024, which was down 34.97% from -$53.1 million recorded in FY2023.
  • Over the past 5 years, Outlook Therapeutics' EBITDA peaked at -$36.8 million during FY2020, and registered a low of -$71.7 million during FY2024.
  • For the 3-year period, Outlook Therapeutics' EBITDA averaged around -$62.6 million, with its median value being -$63.1 million (2022).
  • Per our database at Business Quant, Outlook Therapeutics' EBITDA crashed by 40.41% in 2021 and then rose by 15.77% in 2023.
  • Over the past 5 years, Outlook Therapeutics' EBITDA (Yearly) stood at -$36.8 million in 2020, then plummeted by 40.41% to -$51.7 million in 2021, then fell by 21.93% to -$63.1 million in 2022, then rose by 15.77% to -$53.1 million in 2023, then tumbled by 34.97% to -$71.7 million in 2024.